Chronic kidney disease as a global public health problem: Approaches and initiatives – a position statement from Kidney Disease Improving Global OutcomesAndrew S. Levey, Garabed Eknoyan, R. C. Atkins et al.|Kidney International|2007Cited by 1.5k
Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus ConferenceAndrew S. Levey, Wolfgang C. Winkelmayer, Detlef Böckenhauer et al.|Kidney International|2020Cited by 708
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trialHiddo J.L. Heerspink, Chris Vercammen, Hans‐Henrik Parving et al.|The Lancet|2019Cited by 609
Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated VasculitisDavid Jayne, Annette Bruchfeld, Lorraine Harper et al.|Journal of the American Society of Nephrology|2017Cited by 599
Controversies in acute kidney injury: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) ConferenceMarlies Ostermann, Patricio E. Ray, Rinaldo Bellomo et al.|Kidney International|2020Cited by 548